English EN French FR Spanish ES

Omeza® Collagen Matrix received a Level II Healthcare Common Procedure Coding System (HCPCS) reimbursement code paving the way for providers to receive reimbursement from Medicare. Code A2014, “Omeza collagen matrix, per 100 mg” was set up to describe the product.

Reimbursement for A2014 can be applied from day 1 through the first 28 days of treatment and beyond on as-needed basis in both hospital outpatient departments and physician offices. The reimbursement is not required to be bundled with a procedure.

States Omeza founder and CEO Thomas Gardner, “Achieving this milestone moves us forward in our ambition to be first line of care for wound healing and skin integrity, with an accessible treatment line delivered simply.”

Clinical case studies report an average percentage area reduction (PAR) of 60% at 4 weeks, with 76% of wounds healed in an average of 7 weeks. The novel chronic wound treatment is under clinical investigation to document healing rates in venous leg ulcers, diabetic ulcers, and other chronic wounds.

Omeza® Collagen Matrix is the first of its kind drug-device combination product, with a simple snap and squeeze application for chronic wounds and a 2-year shelf life. It delivers an anhydrous 3-dimensional microstructure of collagen to challenging wounds. When applied to a wound surface, the matrix is naturally incorporated into the wound over time. Omeza® Collagen Matrix is designed for intimate contact with regular and irregular wound beds, providing a conducive environment for the patient’s biological wound healing process.

Omeza ® Collagen Matrix is indicated for the management of wounds including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh’s surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, superficial partial thickness burns, skin tears) and draining wounds.

Earlier this year, Omeza won the “Top Innovation in Wound Care 2022” Award from Wound Management & Prevention (WMP) Journal for its Omeza Products. The Omeza treatment product line consists of the Omeza® Lidocaine Lavage, Omeza® Collagen Matrix Rx, and Omeza® Skin Protectant, created to decrease inflammation, inhibit biofilm, and increase circulation at any site of care.

About Omeza

Omeza Omeza (www.omeza.com) is a skin science company pursuing equitable access to better wound care outcomes for patients at all sites of care. The company is based in Sarasota, FL USA. Inquiries from medical and health professionals should be directed to info@omezapro.com.

English EN French FR Spanish ES